WASHINGTON DC (Jan. 11, 2017) - "We understand the President-Elect's concerns about drug prices. Patients and drug purchasers like the federal government, health systems, employers and others, rely on access to more affordable medicines. Study after study demonstrates that generic medicines drive down drug costs through competition. Still, more can be done to increase competition and we look forward to working with the new Administration to reduce the backlog of generic drug applications at FDA, and on initiatives that bring more generic and biosimilar products to the market. Our recommendations to the Trump administration can be found here and our policy prescriptions to increase pharmaceutical competition are available at www.RxSolutions.us. "
CONTACT:
Rachel Schwartz
202.249.7147 (o)
202.251.8881 (c)